Fulvestrant ('Faslodex') - A new treatment option for patients progressing on prior endocrine therapy

Endocrine-Related Cancer

Volumn 9, Issue 4, 2002, Pages 267-276

  Morris, C ^a   Wakeling, A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; IDOXIFENE; LETROZOLE; MEGESTROL ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHROPATHY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG CHOICE; ESTROGEN METABOLISM; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; OUTCOMES RESEARCH; POSTMENOPAUSE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; URINARY TRACT INFECTION; VAGINITIS; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS;

EID: 0036998677     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0090267     Document Type: Review

References (54)

1. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M & von Eler M 2000 Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of Clinical Oncology 18 3748-3757.
2. Brueggemeier RW 2001 Aromatase, aromatase inhibitors, and breast cancer. American Journal of Therapeutics 8 333-344.
3. Buzdar AU 2001 Endocrine therapy in the treatment of metastatic breast cancer. Seminars in Oncology 28 291-304,
4. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A & Lee D 1998 Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83 1142-1152.
5. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Wincour P & Brannon J 1993 The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology 11 570-579.
6. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS & Bundred NJ 2001 Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. British Journal of Surgery 88 412-418.
7. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG & Singh R 1996 The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Annals of Oncology 7 671-675.
8. Dauvois S, White R & Parker MG 1993 The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science 106 1377-1388.
9. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF & Saunders C 1994 Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Research 54 408-414.
10. Dhingra K 2001 Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer. Cancer Investigation 19 649-659.
11. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U & Trunet PF 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
12. Dowsett M, Dixon JM, Horgan K, Salter J, Hills M & Harvey E 2000 Antiproliferative effects of idoxifene in a placebocontrolled trial in primary human breast cancer. Clinical Cancer Research 6 2260-2267.
13. Dukes M, Miller D, Wakeling AE & Waterton JC 1992 Antiuterotrophic effects of a pure antiestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. Journal of Endocrinology 135 239-247.
14. Erikstein B, Robertson JFR, Osborne KC, Pippen J & Harrison M 2001 ICI 182,780 ('Faslodex') 250 mg monthly intramuscular (i.m.) injection shows consistent PK profile when given as either 1 × 5 ml or 2 ± 2.5 ml injections in postmenopausal women with advanced breast cancer (ABC). Presented at 37th American Society of Clinical Oncology Annual Meeting, 2001, San Francisco (abstract 2025).
15. Espie M 1994 Megestrol acetate in advanced breast carcinoma. Oncology 51 (Suppl 1) 8-12.
16. Fawell SE, White R, Hoare S, Sydenham M, Page M & Parker MG 1990 Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. PNAS 87 6883-6887.
17. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL & Cronin WM 1994 Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Journal of the National Cancer Institutes 86 527-537.
18. Fisher B, Jeong J-H, Dignam J, Anderson S, Mamounas E, Wickerham DL & Wolmark N 2001 Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage 1 breast cancer. Journal of the National Cancer Institute Monographs 30 62-66.
19. Fuqua SA, Fitzgerald SD, Alfred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL & McGuire WL 1992 Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Research 52 483-486.
20. Gill PG, Gebski V, Snyder R, Burns I, Levi J, Byrne M & Coates A 1993 Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Annals of Oncology 4 741-744.
21. Goldenberg IS, Waters N, Ravdin RS, Ansfield FJ & Segaloff A 1973 Androgenic therapy for advanced breast cancer in women. A report of the cooperative breast cancer group. Journal of the American Medical Association 223 1267-1268.
22. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF & Shemano I 1995 Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. Journal of Clinical Oncology 13 2556-2566.
23. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA & Walton P 1996 Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-estrogen ICI 182,780 in women with advanced breast cancer. British Journal of Cancer 74 300-308.
24. Howell A, Osborne CK, Morris C & Wakeling AE 2000 ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 89 817-825.
25. Howell A, Osborne CK, Robertson JFR, Jones SE, Mauriac L, Ellis M, Come S, Vergote I, Buzdar A, Gerther S 2001 ICI 182,780 (Faslodex™) versus anastrozole (ArimidexTM) for the treatment of advanced breast cancer in postmenopausal women - prospective combined analysis of two multicentre trials. European Journal of Cancer 37 151 (abstract 550).
26. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A & Morris C 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 20 3396-3403.
27. Hulka BS 1996 Epidemiology of susceptibility to breast cancer. Progress in Clinical and Biological Research 395 159-174.
28. Johnston SR 2001 Systemic treatment of metastatic breast cancer. Hospital Medicine 62 289-295.
29. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL & Massimini G 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. Journal of Clincial Oncology 18 1399-1411.
30. Lee ES, Schafer JM, Yao K, England G, O'Regan RM, De Los Reyes A & Jordan VC 2000 Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clinical Cancer Research 6 4893-4899.
31. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM & Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF-7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142 2776-2788.
32. Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ & Osborne CK (for the Faslodex Trial 0020 and 0021 Investigators) 2002 Fulvestrant (Faslodex') versus anastrozole for the treatment of advanced breast cancer in a subgroup of postmenopausal women with visceral metastases: combined results from two multicenter trials. European Journal of Cancer 38 (Suppl 3) S96 (abstract 215).
33. Miller WR & Dixon JM 2000 Antiaromatase agents: preclinical data and neoadjuvant therapy. Clinical Breast Cancer 1 (Suppl 1) S9-S14.
34. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA & Dugan M 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 19 2596-2606.
35. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A & von Euler M 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. Journal of Clinical Oncology 18 3758-3767.
36. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG & Wakeling AE 1994 The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemotherapy and Pharmacology 34 89-95.
37. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL & Nicholson RI 1995 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 87 746-750.
38. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R & Buzdar A 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 20 3386-3395.
39. Parker LM & Webster A 2002 Greater duration of response in postmenopausal patients receiving fulvestrant ('faslodex') compared with those receiving anastrozole. Presented at 38th American Society of Clinical Oncology Annual Meeting, 2002, Orlando, Florida (abstract 160).
40. Perey L, Thürlimann B, Hawle H, Bonnefoi H, Aebi S, Pagani O, Goldhirsch A & Dietrich D 2002 For the Swiss Group for Clinical Cancer Research for Clinical Cancer Research (SAKK). Fulvestrant ('Faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and non-steroidal aromatase inhibitors: an ongoing phase II SAKK trial. Annals of Oncology 13 (Suppl 5) S 48 (abstract P172).
41. Powles TJ, Hickish T, Kanis JA, Tidy A & Ashley S 1996 Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology 14 78-84.
42. Pritchard KI & Sutherland DJA 1989 Diagnosis and therapy of breast cancer: the use of endocrine therapy. Hematology/Oncology Clinics of North America 3 765-805.
43. Rauschning W & Pritchard KI 1994 Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Research and Treatment 31 83-94.
44. Robertson JFR 2000 A comparison of the single-dose pharmacokinetics of ICI 182,780 ('Faslodex') 250 mg when given as either a one × 5-ml intramuscular injection or two × 2.5-ml injections in postmenopausal women with advanced breast cancer. Breast Cancer Research and Treatment 64 53 (abstract 172).
45. Robertson JFR, Nicholson R, Gee J, Odling-Smee W, Holcombe C, Kohlhardt SR et al. 2000 The pharmacokinetics of single dose Faslodex (TM) (ICI 182,780) in postmenopausal primary breast cancer - relationship with estrogen receptor (ER) down regulation. Presented at 36th American Society of Clinical Oncology Annual Meeting, 2000, New Orleans, LA (abstract 362).
46. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C & Dixon M 2001 Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Research 6 6739-6746.
47. Robertson JFR, Howell A, Abram P, Lichinitser MR & Elledge R 2002 Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Annals of Oncology 13 (Suppl 5) 46 (abstract 1640).
48. The ATAC Trialists' Group 2002 Arimidex, tamoxifen alone or in combination. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 2131-2139.
49. Thiebaud D & Secrest RJ 2001 Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene. Reproduction, Fertility and Development 13 331-336.
50. Vergote I 2002 Evidence of continued sensitivity to endocrine agents in postmenopausal women with advanced breast cancer progressing on fulvestrant ('Faslodex') treatment. European Journal of Cancer 38 (Suppl 3) S96 (abstract 216).
51. Wakeling AE 2000 Similarities and distinctions in the mode of action of different classes of antiestrogens. Endocrine-Related Cancer 7 17-28.
52. Wakeling AE & Bowler J 1987 Steroidal pure antiestrogens. Journal of Endocrinology 112 R7-R10.
53. Wakeling AE, Dukes M & Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Research 5 3867-3873.
54. Wolf DM, Jordan VC & William L 1993 McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Research and Treatment 27 27-40.